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Exploring temporal disease progression and comorbidities in
psoriatic disease
Nana A.L. Rosenø, MSc, Department of Dermatology, Copenhagen
University Hospital - Bispebjerg and Frederiksberg, Copenhagen,
Denmark; Erik Hillo Lørup, MSc, Department of Dermatology, Copenhagen
University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark;
Ivette Alarcon, MD, Novartis Pharma AG, Basel, Switzerland
Psoriasis is associated with multiple systemic comorbid conditions. Most registry
studies fail to recapitulate correlations between psoriasis and the temporal
progression of broader diseases. Here, a holistic overview of the correlations of
disease characteristics with temporal disease progression and long-term disease
trajectories of psoriatic patients is explored. This observational, retrospective,
noninterventional study identified psoriatic patients in the Danish National Patient
Registry with an International Statistical Classification of Diseases and Related
Health Problems-10th edition (ICD-10) code for psoriasis (L40.0 or L40.9) from
1999e2013. Relative risk (RR) measured strength of association between psoriasis
and frequent disease co-occurrences to create disease trajectory clusters. All
significant disease pairs (D1[D2) with an RR[1 and P D2 (D1 ¼ psoriasis, D2 ¼
any other ICD-10). 38/121 achieved RR[1; P D2 (median time range ¼ 3-7 years).
Crohn’s disease (ICD-10 ¼ K50) had a significant association to and from psoriasis
diagnosis: RR ¼ 1.36 [CI:1.34; 1.39] P K50) and RR ¼ 1.56 [CI:1.53; 1.59] P
psoriasis). The highest RR in both directions of psoriasis was enteropathic
arthropathies (ICD-10 ¼ M07): RR ¼ 32.28 ([95% CI 32.16-32.41]; P M07 and RR
¼ 39.35 [95% CI 39.22-39.47]; P psoriasis). 4/5 disease trajectories with 3 diagnoses
had a significant direction from psoriasis[D2[D3 and an RR[1; P \.001. Disease
trajectory clusters may facilitate clinicians in planning risk stratification of patients
to identify optimal treatment options and prevent future comorbidities.
Commercial Disclosure: Sponsored by Novartis Pharma AG, Basel, Switzerland.
Editorial and writing support funded by Novartis Pharm AG, in accordance with
GGP3.
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Expression of interleukin 36 receptor antagonist in a patient
with generalized pustular psoriasis harboring the p.Pro82Leu
variant in the IL36RN gene
Itsumi Mizukawa, MD, Department of Dermatology, Teikyo University
School of Medicine; Masahiro Kamata, MD, PhD, Department of Dermatology,
Teikyo University School of Medicine; Hideaki Uchida, MD, Department of
Dermatology, Teikyo University School of Medicine
Background: Mutation of the IL36RN gene contributes to the development of
generalized pustular psoriasis (GPP). The IL36RN gene encodes interleukin (IL)-36
receptor antagonist (IL-36Ra), which has antagonistic roles against IL-36. Li et al.
performed sanger sequencing to identify IL36RN mutations in 62 Chinese GPP
patients, and reported a new variant, c.245C[T (p.Pro82Leu) in a patient with GPP.
Since this p.Pro82Leu variant was not found in the psoriasis vulgaris and control
groups in their study, they speculated that this variant might lead to exacerbated
inflammatory responses. Meanwhile, SIFT and PolyPhen-2, pathogenicity prediction
tools, predict this variant as tolerated and benign. To date, its pathogenicity was
unknown.
Objective: To investigate the mRNA and protein expressions of IL-36Ra in a patient
with GPP harboring the p.Pro82Leu variant.
Methods: To investigate mRNA expression of IL36RN, polymerase chain reaction
was conducted on hair samples obtained from the patient and a healthy control
using primers to detect mRNA of exons 2 and 5 in IL36RN. Immunohistochemical
staining for IL-36Ra was performed to detect its protein expression.
Results: Gene analysis on blood obtained from a 76-year-old Japanese man with GPP
demonstrated a mutation in IL36RN (c.245C[T). In the patient, mRNA expression
of IL36RN was observed. Immunohistochemical staining revealed that IL-36Ra was
expressed in the keratinocytes of the patient with GPP harboring the p.Pro82Leu as
in those of the GPP patient without the mutation.
Conclusion: Our results indicate no aberrant splicing nor pathogenicity in this
variant. This variant is not associated with the development of GPP.
Commercial Disclosure: None identified.
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Health System; Justin Olson, Ashley Furniture, Photomedicine,
Photobiology Unit, Henry Ford Health System
Frontal fibrosing alopecia (FFA) is an immune-mediated cicatricial alopecia. Skin
care products including sunscreen were suggested to influence disease pathogenesis. Given the conflicting data, the aim of this study is to provide a quantitative
summary on this topic. A systematic search surveying PubMed database was
conducted in August 2021. The Preferred Reporting Items for Systematic Reviews
and Meta-analyses guidelines were followed. The study was prospectively registered
in Prospero (ID: 273840). The pooled effect size is presented as odds ratio (OR) with
95% confidence interval (CI). A total of 87 articles were identified; 9 articles were
included. Using the Newcastle Ottawa scale (NOS), the quality of studies ranged
from 5 to 7, suggestive of moderate quality. 1248 patients in the published literature
had FFA (mean age: 58.9, 95.7% female) and were compared with 1459 control
subjects (mean age: 56.9, 89.8% female). Six (66.67%) studies assessed the use of
sunscreen and moisturizers 5 years before the onset of FFA. Nine studies evaluated
the association between sunscreen and FFA (n ¼ 9); the pooled OR was 1.45 95%CI
[1.11-1.90], P ¼ .0068. For the 8 studies exploring the relationship between facial
moisturizers and FFA, the pooled OR was 1.26 (95% CI 1.10-1.43), P ¼ .006. The
results of this study suggest that both sunscreen and moisturizers likely increase the
risk of FFA by 45% and 26% respectively. Due to lack of randomized controlled trials
and small number of studies, the causality of this association could not be
ascertained. As such, high-quality studies are needed.
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Extraocular sebaceous carcinoma in a patient on long-term
methotrexate therapy
Richa Nagpal, MD, Consultant Dermatologist, Rita Skin Foundation,
Kolkata, India; Vinoo Sekhri, MD, Consultant Dermatopathologist,
Fortis Hospital, Noida, India; Rajiv Sekhri, MD, Consultant Dermatologist,
Fortis Hospital, Noida, India
Introduction: Sebaceous carcinoma (SC) is a rare and aggressive malignant tumor
that arises from the adnexal epithelium of the sebaceous glands. It can either occur
sporadically or in association with Muir-Torre syndrome (MTS), wherein these
tumors are associated with internal malignancies. Chronic immunosuppression is a
known risk factor for the development of SC with reports of its occurrence in
patients on long term azathioprine and cyclosporine therapy. It has been suggested
that immunosuppressive drugs could directly interact with DNA mismatch repair
mechanism or might unmask a previously silent MTS phenotype predisposing to
their development. This case describes the occurrence of SC in a patient on long
term methotrexate therapy which has never been reported before.
Case Report: A 54-year-old male, on low dose methotrexate therapy for the
management of limited scleroderma for past 12 years presented with a yellowishpink ulcerated exophytic mass on the right parietal area of scalp for past one year.
Histopathology revealed a dermal tumor composed of lobules and nests of cells
having variable sebaceous differentiation with focal necrosis, scattered mitoses and
atypical forms. A diagnosis of SC was made and the patient was sent to the surgical
oncologist. No evidence of metastasis was found and wide local excision of the
tumor was done with margins. Histopathologic evaluation of the specimen
confirmed SC of grade 1 with TNM path stage of pT3 (size [4 cm, depth of invasion
of 2 mm). The patient did well postoperatively and was counselled for close followup with the oncologist.
Commercial Disclosure: None identified.

J AM ACAD DERMATOL

AB59

